Guselkumab in Crohn's disease: the IL-23 race continues

Lancet Gastroenterol Hepatol. 2024 Feb;9(2):97-98. doi: 10.1016/S2468-1253(23)00356-4. Epub 2023 Dec 14.

Authors

Mathurin Fumery¹, Anthony Buisson²

Affiliations

¹ Department of Gastroenterology, CHU Amiens and PériTox, UMR-I 01 INERIS, Picardie Jules Verne University, Amiens, France. Electronic address: fumery.mathurin@chu-amiens.fr.
² Université Clermont Auvergne, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Inserm U1071, M2iSH, USC-INRA 2018, Clermont-Ferrand, France.

PMID: 38104570
DOI: 10.1016/S2468-1253(23)00356-4

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Crohn Disease* / drug therapy
Humans
Interleukin-23

Substances

guselkumab
Antibodies, Monoclonal, Humanized
Interleukin-23